AR050536A1 - Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden - Google Patents
Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR050536A1 AR050536A1 ARP050103593A ARP050103593A AR050536A1 AR 050536 A1 AR050536 A1 AR 050536A1 AR P050103593 A ARP050103593 A AR P050103593A AR P050103593 A ARP050103593 A AR P050103593A AR 050536 A1 AR050536 A1 AR 050536A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- hydrogen
- alkoxy
- independently selected
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente comprende procesos para su produccion, a su uso como productos farmacéuticos y a composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de formula (1), donde R0 es hidrogeno; R1 es un monocíclico de 6 miembros no susituido o sustituido o un heterociclo bicíclico de 10 miembros que comprende 1 o 2 heteroátomos seleccionados independientemente de N y O; R2 y R3 junto con el C y N a los cuales se encuentran unidos forman un heterociclo que comprende al menos 1 heteroátomo seleccionado independientemente de N que está no sustituido o sustituido una o más veces por un sustituyente seleccionado independientemente de alquilo inferior y oxo; R4 es hidrogeno; R5 es halogeno; R6 es hidrogeno; R7 es hidrogeno; R8 es hidrogeno; alcoxi C1-7; carbamoílo no sustituido o sustituido por alquilo C1-7; alcoxi C1-7-alcoxi C1-7; un heterociclo de 5 o 6 miembros que comprende 1, 2 heteroátomos seleccionados independientemente de N u O y está no sustituido o sustituido por un sustituyente seleccionado independientemente de hidroxi, alquilo C1-7, mono o di-alquilamino C1-7, un heterociclo de 6 miembros que comprende 1 o 2 átomos de N anulares no sustituido o sustituido por alquilo C1-7; heterociclil de 5 o 6 miembros-alcoxi C1-7 que comprende 1 átomo de n anular no sustituido o sustituido por alquilo C1-7; R9 es hidrogeno; R10 es hidrogeno, halogeno o alcoxi C1-7; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0419160.7A GB0419160D0 (en) | 2004-08-27 | 2004-08-27 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050536A1 true AR050536A1 (es) | 2006-11-01 |
Family
ID=33104745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103593A AR050536A1 (es) | 2004-08-27 | 2005-08-26 | Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7910585B2 (es) |
| EP (1) | EP1784399B1 (es) |
| JP (1) | JP4674236B2 (es) |
| KR (1) | KR100894349B1 (es) |
| CN (1) | CN101006079A (es) |
| AR (1) | AR050536A1 (es) |
| AT (1) | ATE512960T1 (es) |
| AU (1) | AU2005276585B2 (es) |
| BR (1) | BRPI0514731A (es) |
| CA (1) | CA2575720C (es) |
| EC (1) | ECSP077259A (es) |
| ES (1) | ES2366038T3 (es) |
| GB (1) | GB0419160D0 (es) |
| GT (1) | GT200500229A (es) |
| IL (1) | IL181386A0 (es) |
| MA (1) | MA28813B1 (es) |
| NO (1) | NO20071504L (es) |
| PE (1) | PE20060504A1 (es) |
| PL (1) | PL1784399T3 (es) |
| PT (1) | PT1784399E (es) |
| RU (1) | RU2395507C2 (es) |
| TN (1) | TNSN07074A1 (es) |
| TW (1) | TW200621728A (es) |
| WO (1) | WO2006021457A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP2447360A1 (en) | 2006-04-14 | 2012-05-02 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| TWI432427B (zh) | 2006-10-23 | 2014-04-01 | Cephalon Inc | 作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物 |
| US8039479B2 (en) | 2006-12-08 | 2011-10-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2010513272A (ja) * | 2006-12-14 | 2010-04-30 | メルク エンド カムパニー インコーポレーテッド | アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EP2303861B1 (en) | 2008-06-17 | 2014-04-23 | AstraZeneca AB | Pyridine compounds |
| JO3067B1 (ar) * | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| TWI491605B (zh) * | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | 新穎化合物 |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| CN101935317B (zh) * | 2009-07-01 | 2013-08-28 | 上海药明康德新药开发有限公司 | 2-甲基-7-(取代嘧啶-4-氨基)-4-(取代哌啶-1-基)异吲哚啉-1-酮及中间体的合成方法 |
| TWI513694B (zh) * | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| JP6000273B2 (ja) * | 2010-11-29 | 2016-09-28 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 大環状キナーゼ阻害剤 |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2014126125A1 (ja) | 2013-02-13 | 2014-08-21 | 学校法人福岡大学 | 迅速アレルギー検査方法 |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| KR20220105631A (ko) * | 2019-09-13 | 2022-07-27 | 님버스 새턴 인코포레이티드 | Hpk1 길항제 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6776480B2 (en) | 2001-07-18 | 2004-08-17 | Sola International Holdings, Ltd. | Spectacle frames for shaped lenses defined by monoformal carrier surfaces |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003231231A1 (en) * | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
-
2004
- 2004-08-27 GB GBGB0419160.7A patent/GB0419160D0/en not_active Ceased
-
2005
- 2005-08-25 PE PE2005000980A patent/PE20060504A1/es not_active Application Discontinuation
- 2005-08-26 BR BRPI0514731-0A patent/BRPI0514731A/pt not_active IP Right Cessation
- 2005-08-26 EP EP05782820A patent/EP1784399B1/en active Active
- 2005-08-26 CA CA2575720A patent/CA2575720C/en not_active Expired - Fee Related
- 2005-08-26 WO PCT/EP2005/009255 patent/WO2006021457A2/en active Application Filing
- 2005-08-26 GT GT200500229A patent/GT200500229A/es unknown
- 2005-08-26 RU RU2007110946/04A patent/RU2395507C2/ru not_active IP Right Cessation
- 2005-08-26 AT AT05782820T patent/ATE512960T1/de active
- 2005-08-26 PL PL05782820T patent/PL1784399T3/pl unknown
- 2005-08-26 CN CNA2005800280957A patent/CN101006079A/zh active Pending
- 2005-08-26 JP JP2007528756A patent/JP4674236B2/ja not_active Expired - Fee Related
- 2005-08-26 KR KR1020077004528A patent/KR100894349B1/ko not_active IP Right Cessation
- 2005-08-26 AU AU2005276585A patent/AU2005276585B2/en not_active Ceased
- 2005-08-26 AR ARP050103593A patent/AR050536A1/es not_active Application Discontinuation
- 2005-08-26 PT PT05782820T patent/PT1784399E/pt unknown
- 2005-08-26 ES ES05782820T patent/ES2366038T3/es active Active
- 2005-08-26 US US11/660,714 patent/US7910585B2/en not_active Expired - Fee Related
- 2005-08-26 TW TW094129174A patent/TW200621728A/zh unknown
-
2007
- 2007-02-15 IL IL181386A patent/IL181386A0/en unknown
- 2007-02-15 EC EC2007007259A patent/ECSP077259A/es unknown
- 2007-02-21 MA MA29698A patent/MA28813B1/fr unknown
- 2007-02-26 TN TNP2007000074A patent/TNSN07074A1/en unknown
- 2007-03-22 NO NO20071504A patent/NO20071504L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1784399E (pt) | 2011-08-26 |
| GB0419160D0 (en) | 2004-09-29 |
| ECSP077259A (es) | 2007-03-29 |
| CA2575720C (en) | 2012-10-02 |
| ATE512960T1 (de) | 2011-07-15 |
| RU2395507C2 (ru) | 2010-07-27 |
| WO2006021457A2 (en) | 2006-03-02 |
| JP2008510765A (ja) | 2008-04-10 |
| AU2005276585A1 (en) | 2006-03-02 |
| PL1784399T3 (pl) | 2011-11-30 |
| GT200500229A (es) | 2006-03-29 |
| KR20070038567A (ko) | 2007-04-10 |
| US7910585B2 (en) | 2011-03-22 |
| US20080293708A1 (en) | 2008-11-27 |
| EP1784399B1 (en) | 2011-06-15 |
| AU2005276585B2 (en) | 2009-07-30 |
| ES2366038T3 (es) | 2011-10-14 |
| IL181386A0 (en) | 2007-07-04 |
| JP4674236B2 (ja) | 2011-04-20 |
| WO2006021457A3 (en) | 2006-07-13 |
| EP1784399A2 (en) | 2007-05-16 |
| CA2575720A1 (en) | 2006-03-02 |
| BRPI0514731A (pt) | 2008-06-24 |
| CN101006079A (zh) | 2007-07-25 |
| TNSN07074A1 (en) | 2008-06-02 |
| TW200621728A (en) | 2006-07-01 |
| NO20071504L (no) | 2007-05-25 |
| RU2007110946A (ru) | 2008-10-10 |
| PE20060504A1 (es) | 2006-07-18 |
| MA28813B1 (fr) | 2007-08-01 |
| KR100894349B1 (ko) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050536A1 (es) | Derivados de pirimidina, procesos de preparacion y composiciones farmaceuticas que los comprenden | |
| AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR108011A1 (es) | Moduladores receptores de estrógenos | |
| CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
| CL2018001325A1 (es) | Derivados de indol n-sustituidos como moduladores del receptor de pge2 | |
| CO6280476A2 (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
| CL2021002165A1 (es) | Nuevos derivados de compuestos heterociclicos y uso de los mismos | |
| ES2630079T3 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR073412A1 (es) | Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende. | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| CO2019010804A2 (es) | Derivados de indol n–sustituidos | |
| CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
| BR112012013511A2 (pt) | derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear | |
| PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
| AR078632A1 (es) | Compuestos esteroidales modificadores de la melanogenesis y sus usos | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR078722A1 (es) | Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol | |
| AR099867A1 (es) | Compuestos imidazobenzotiazolo fusionados | |
| ECSP22027287A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| PE20221732A1 (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |